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Abstract
Lung cancer is one of the most common cancer types in men and women worldwide with a high
mortality rate. World Health Organization (WHO) classification has accepted biopsy as the primary
sample for lung cancer diagnosis, pathological classification and molecular testing for management
of patients, yet, the use of alternative sampling procedures is highly encouraged. Bronchial cyto-
logical samples require a less invasive collection technique and may be suitable for pathological
and molecular analysis and storage in liquid medium. Furthermore, the molecular analysis of bron-
chial cytological samples allows the detection of molecular biomarkers, which may be useful for
the selection of molecular targeted therapies. Thus, the purpose of this review is to describe the
usefulness of bronchial cytological samples preserved in liquid medium from lung cancer patients
for pathological diagnosis and molecular investigation.
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1 | INTRODUCTION
Lung cancer is the major cause of cancer-related death among men
and the second most common among women worldwide.1 The Interna-
tional Agency for Research on Cancer (IARC) reported that almost 1.6
million deaths in 2012 were due to lung cancer and estimated 1.8 mil-
lion new cases for 2016.2 Only 15% of lung cancer cases are diagnosed
at the initial stages of the disease, when the treatment is more effec-
tive, rendering a low overall survival rate of approximately 17%.3,4
In 2015, for the first time, the World Health Organization (WHO)
classification proposed new criteria for the diagnosis of lung cancer
based on small biopsies (bronchoscopic, needle or core biopsies) and
cytology. For the collection of these biopsies, surgical resection is not
required, resulting in a less invasive procedure for collection of speci-
mens.5 These specimens are used for pathological classification, allow-
ing the diagnosis of advanced stages of the disease, as well as for
molecular testing to guide the treatment of patients, especially in inop-
erable cases.6,7 The major objective of biopsy is to establish the diagno-
sis and stage of disease and minimize the risk to the patient.8 Based on
the high demand for these small specimens with limited tissue, the use
of alternative samples is highly encouraged.8–10 Cytological smears and
liquid-based cytology may be a less invasive option to avoid re-biopsy.
This scenario was noted by the WHO in 2004, when the cytology was
included for the first time as an acceptable diagnostic sample, and
more recently by the Papanicolaou Society of Cytopathology Guide-
lines published for Standardized Terminology and Nomenclature for
Respiratory Cytology.11 However, since then, the employment of cyto-
logical samples has been mostly limited to ancillary samples for diagno-
sis. Herein, we will focus in the main clinical and molecular aspects of
lung cancer as well as the advantages of liquid-based cytology (LBC)
for lung cancer diagnosis.
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1.1 | Collecting bronchial samples
Before showing the main aspects of lung cancer and the advantages of
liquid cytology for the study of neoplastic or potentially neoplastic dis-
ease and the investigation of a variety of benign diseases, including
opportunistic infections,12 we will briefly discuss the sampling proce-
dure. The most common methods to obtain cytological specimens
include fine-needle aspirates (FNAs) from lung (frequently coupled with
core needle biopsies), bronchial brushings, bronchial washings, bron-
choalveolar lavages and sputum, along other minimally invasive aspira-
tions of distant, deep-seated or superficial metastatic lesions.13
Fine-needle aspirates (FNAs): as a collection method, the sensitivity
and specificity for the diagnosis of lung cancer is high with an accepta-
ble complication rate.14
Bronchial brushings: an useful option in endoscopically visible
tumors, it can be performed before or after biopsy sampling, but it is
advisable to be perform it before the bronchial biopsy to avoid contam-
ination of the specimen with blood.15,16 For adequate representative-
ness of the suspect malignancy area, the brush should be forward/
reverse two or three times.17
Bronchial washing: it can also be taken before or after biopsy sam-
pling. The exact volume to be recovered from this procedure has not
been established; however, several studies recommend recovering as
much fluid as possible after instilling 20-30 mL of sterile isotonic
saline.15 The material is centrifuged and the sediment is used to pre-
pare the smears or liquid-based preparations, which is then stained.17
Bronchoalveolar lavage (BAL): this technique increases the diagnos-
tic yield in pulmonary peripheral lesions, and it is primarily used to diag-
nose infections and interstitial lung diseases.18 Unlike the other
techniques, BAL has well-standardized guidelines.17
Sputum: it is not recommended as a suitable material for diagnosis
of lung cancer due to its low sensitivity.19 In patients who are unable
to undergo bronchoscopy or other minimally invasive procedure and
for whom a diagnosis of malignancy is required, sputum may be helpful.
It is recommended to repeat sputum sampling over several days for
increased sensitivity.17,19
First, we would like to highlight that cytological samples are con-
sidered an important tool for the diagnosis of lung cancer due to their
low cost and less invasive collection methods.17,20
1.2 | Lung cancer: current aspects
The pathogenesis of lung cancer is complex and it may occur due to a
combination of genetic and environmental factors.21 Although smoking
habits is the strongest factor linked to lung cancer, the incidence of the
disease among non-smokers has increased.22 In addition to smoking,
other factors are also related to lung cancer such as occupational expo-
sure, previous lung disease and diet among others are attracting the
attention of the physicians to patients who do not smoke.22–24 Based
on this, we can suppose that additional factors might be the cause of
the disease and they can function independently or in combination
with the well-known factors.23,25
Regarding the histology, lung cancer is classified into two main
groups: Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer
(NSCLC).26,27 For many years, this histological classification of lung
cancer was sufficient for the management of lung cancer patients in
routine practice.5
1.3 | Small Cell Lung Cancer (SCLC)
Previously described as ‘oat cell carcinoma’ in a patient with asbestosis,
SCLC exhibits neuroendocrine differentiation, strong association with
smoking and genomic alterations enrolling genes with a key role in
transcriptional regulation and chromatin modification.28,29 Patients
with SCLC have carcinomas which display a high growth fraction, rapid
doubling time and early establishment of widespread metastatic lesions
and response to first-line chemotherapy. Nonetheless, SCLC patients
experience relapse, and there is no approved targeted drug as a second
line therapy for these tumors.30 However, this scenario may change
since many promising advances with immune checkpoint inhibitors
have emerged in the last few years.31,32
Genomic analyses have identified driver mutations in SCLC, leading
to a better understanding about cellular features and molecular mecha-
nisms involved in initiation, progression, metastasis and resistance.33
However, limited tumor tissue for research due to small diagnostic
biopsies represents a significant barrier to progress in the research
field,28,34 which can be circumvented using cytological samples.
Basically, lung carcinoma differentiation into SCLC and NSCLC
subsets is important for the clinical management of the patients. The
first step for the diagnosis is the observation of cytological features
from tumor samples. The diagnosis of SCLC can be achieved through
cytomorphology of FNA prepared using ThinPrep and conventional
smears.35 Indeed, the LBC of sputum specimens from 101 patients
with lung cancer exhibited a significantly higher sensitivity for SCLC
diagnosis (P< .05) than conventional smear, suggesting the LBC may
be easily and widely applied for lung cancer diagnosis.36 The diagnostic
value of LBC was also shown using 4,380 brushing specimens from
lung cancer patients. The accuracy was 75.6% and, compared with his-
topathology—gold standard, the LBC allowed lung cancer subtyping
into squamous cell carcinoma, adenocarcinoma and small cell carci-
noma with accuracy rates of 95.6% (351/367), 95.6% (351/367) and
100% (367/367), respectively (P< .001), with the highest value for
SCLC. These results emphasize that LBC is an effective tool for the
diagnosis and subtyping of lung cancer.37 and should be better
exploited.
1.4 | Non-Small Cell Lung Cancer (NSCLC)
The NSCLC group can be further subdivided into three major cell
types: adenocarcinoma, squamous cell carcinoma and large cell carci-
noma. Adenocarcinoma is the most common histological type and gen-
erally arises in the distal airways.38 Squamous cell carcinoma usually
arises in the proximal airways and in the hilum or close to it.38,39 Large
cell carcinoma is diagnosed by exclusion, when the tumor cells do not
present glandular or squamous appearance and present with distinctive
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histological elements, giant cells and clear cells.39 Among all cases of
lung cancer, approximately 80%-85% are diagnosed as NSCLC, and
among all NSCLC cases, almost 70% are locally advanced or meta-
static.40 For metastatic NSCLC cases, chemotherapy, targeted therapy
and/or radiation therapy are not effective for disease cure and they
can only extend survival and palliate the symptoms.
In general, the diagnosis of lung cancer involves three important
steps: (I) identification and classification of malignancy, (II) immunohis-
tochemistry to predict the likely NSCLC subtype and (III) molecular
testing, mainly in advanced adenocarcinoma to investigate oncogenic
driver mutations.17 The evidence of therapeutically relevant driver
mutations in subsets of NSCLC and the emerging drugs as targeted
therapies for some subtypes of NSCLC have rendered the classification
of NSCLC subtypes clinically mandatory.5
1.5 | Lung cancer: molecular landscape
1.5.1 | EGFR
Mutations in the epidermal growth factor receptor (EGFR) gene activate
this receptor, which leads to the activation of intracellular signaling
pathways involved in cell proliferation, differentiation and cell cycle,
triggering neoplastic progression. The most common mutations are
located between exons 19 and 21 and they are frequently observed in
some types of lung cancers especially adenocarcinomas. Among
NSCLC, EGFR hotspot mutations are found in approximately 10%-15%
of all tumors, being more common in female patients, non-smokers
and Asian patients, in which the frequency of these mutations is
improved.41,42 The presence of EGFR mutations is related to the prog-
nosis of NSCLC patients, sensitivity and improved response to tyrosine
kinase inhibitors (TKIs) such as erlotinib and gefitinib.43–47
1.5.2 | KRAS
Mutations in the kirsten rat sarcoma viral oncogene homolog (KRAS)
oncogene have been associated with several malignancies including as
pancreatic cancer, colorectal cancer and lung cancer.48–50 KRAS muta-
tions occur in approximately 20% of NSCLC patients and are com-
monly located at codons 12 and 13 of the gene. These mutations are
associated with smoking habits, have a worse prognosis and are more
common in the NSCLC subtype.38,51,52 Patients harboring KRAS, unlike
EGFR-mutated patients, do not benefit from TKIs, probably because
KRAS itself is difficult to inhibit, and the effectiveness of agents target-
ing KRAS effectors have been blocked by the activation of offsetting
pathways that limit their efficiency.53,54
1.5.3 | EML4-ALK
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor translo-
cations of which trigger an oncogenic process in NSCLC tumors.55 The
echinoderm microtubule associated protein like 4 (EML4) gene is
located near to ALK gene.55 An inversion in the short arm of chromo-
some 2 results in a fusion gene comprising parts of the ALK and EML4
genes. The protein encoded by this gene-fusion gene is highly onco-
genic and associated with NSCLC pathogenesis in a subgroup of
patients.55 ALK-EML4 translocations and EGFR and KRAS mutations are
mutually exclusive.56,57 The oral inhibitor of the ALK tyrosine kinase
domain, crizotinib, was effective in decreasing in vitro cell proliferation
and to improve overall and disease-free survival in NSCLC patients har-
boring ALK-EML4 translocations.58,59 However, the frequency of this
alteration in patients with NSCLC is low, approximately 3%–7%.55–57,60
1.6 | Molecular biomarkers in body fluids
In the last few years, many studies have emerged to investigate lung
cancer biomarkers, which have been defined for prognostic purposes,
diagnosis and early detection of the disease. The detection of bio-
markers can help to define tumor stage, recognition of recurrence, and
to support disease and treatment monitoring.61 These biomarkers may
be proteins, RNA molecules, miRNAs, methylated DNAs and, more
recently, circulating tumor cells.62 Tumor biomarkers are secreted by
the neoplastic tissue into body fluids and help to distinguish abnormal
from normal conditions.50,63 Body fluids are generally easily obtained
and may be routinely collected for laboratory testing. Among body flu-
ids in lung cancer patients, bronchial washes are obtained in a volume
sufficient to allow its use in molecular biomarker identification.
1.6.1 | Molecular biomarkers and clinical relevance
for lung cancer patients
In routine practice, patients with advanced adenocarcinomas are cur-
rently tested for EGFR mutations and ALK aberrations.5 Since 2009,
several clinical trials have reported better response rates and increased
progression-free survival in patients with advanced NSCLC with muta-
tions in EGFR gene who received TKIs compared with conventional
therapy.64–66 Since most patients with early-stage lung cancer will
eventually experienced relapse and disease progression, the College of
American Pathologists (CAP), the International Association for the
Study of Lung Cancer (IASLC) and the Association for Molecular
Pathology (AMP) have developed a guideline encouraging EGFR and
ALK testing for lung cancer at the time of diagnosis for patients pre-
senting with advanced disease stage to guide clinical management with
targeted therapies.47,59,67
ALK-EML4 translocations and EGFR and KRAS mutations are mutu-
ally exclusive.33,34 Thus, when EGFR and KRAS mutations are absent,
the detection of ALK-EML4 translocations is crucial for a favorable
response to crizotinib.68 Until now, the only FDA-approved laboratory
test to detect ALK-EML4 translocations is fluorescence in situ hybrid-
ization (FISH), which allows direct visualization of multiple changes in
chromosomes and in the number of gene copies.69 However, new
technologies have emerged, such as NanoString, to detect this altera-
tion, including other gene fusions such as fusion comprising the RET
and ROS1 genes.70
Different from EGFR-mutated patients, those harboring KRAS
mutations do not benefit from TKIs. The main reason for this problem
is probably because KRAS itself is difficult to inhibit, and the effective-
ness of agents targeting KRAS effectors has been blocked by the acti-
vation of offsetting pathways limiting their efficiency.53,54 To date,
there is no effective targeted therapy for patients harboring KRAS
mutations.71 Trametinib acts downstream of KRAS and suppresses the
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MAPK signaling; however, it was recently demonstrated that trameti-
nib provokes a compensatory response mediated by the fibroblast
growth factor receptor 1 (FGFR1), leading to adaptive drug resistance
and FGFR1 inhibition increased sensitivity to trametinib. These data
paved the way for a combinatorial approach to treat KRAS-mutant lung
cancer and open opportunities for effective treatment for these
patients.72
1.7 | Liquid medium beyond cytology
The concept of personalized medicine of lung cancer is based on the
therapeutic decisions driven by the specific histology and genetic fea-
tures of patient’s tumor. However, the biopsy techniques traditionally
performed provide limited specimens that usually are insufficient for all
tests and frequently require re-biopsy the performance of which
depends on the patients clinical situation.5
In this sense, cytological samples are an attractive tool to help in
the management of patients with lung cancer because it enables
genomic and proteomic assays beyond cellular analysis, with the
advantage of being enriched in tumor cells and not formalin-
fixed.20,73,74
Thus, the maintenance of cytologic bronchial material in liquid
medium, initially used for gynecological issue (LBC), represents an use-
ful method. This is, especially true in cases where there is no option to
immediately prepare the smear. These liquid-based methods, preserve
the morphology of cells at room temperature for a long time until labo-
ratorial processing can occur (Figure 1).
1.7.1 | Assessing molecular biomarkers
in cytological samples
Among molecular laboratory tests for assessing EGFR mutations in
cytological samples, PCR-based techniques can be highlighted including
direct sequencing, real-time PCR, pyrosequencing, fragment length
analysis and high resolution melting analysis, amplification-refractory
mutation system, peptide nucleic acid-locked nucleic acid, low denatu-
ration temperature co-amplification and next-generation sequencing
(NGS).20 FISH (fluorescence in situ hybridization), employed for the
detection of ALK rearrangements, has been shown to be significantly
more sensitive to detect cancer in brushed bronchial specimens than
conventional cytology, and it allows the detection of tumors in early
stages and those tumours peripherally located. In addition, there are
reports describing immunocytochemistry (ICQ) applying anti-ALK anti-
bodies as a faster and low-cost alternative to FISH assays in cytological
samples.73
Beyond that, differentially expressed proteins can be easily
detected using specific antibodies in ICQ technique, and the detection
of these proteins reflects signaling pathways activation or inactivation,
which contributes for the identification of molecular aspects of lung
cancer in cytological samples.75
Likewise, flow cytometry is widely used to quantify cells and
inflammatory molecules. This technique may be carried out using
cytology samples from BAL specimens. Several studies have shown
that flow cytometry is useful to differentiate CD41, CD81 and
CD561 lymphocytes, which are present in BAL specimens from both
in lung cancer and in pulmonary diseases such as asthma.76 BAL pro-
vides non-cellular components of the fluid covering the respiratory epi-
thelium and allows the quantification of cytokines (e.g., IL-6 and IL-1 b)
employing cytometry beads-assay.77,78
Another approach that highly fits employing cytological samples is
next-generation sequencing (NGS), which uses a simple platform to
assess several variations such as single-nucleotide polymorphisms
(SNPs), insertions and deletions, as well as gene amplifications and rear-
rangements73,79 Very recently, a complete workflow for detection of
low frequency somatic mutations from cell-free DNA was developed
for a NGS platform. Basically, the workflow consists of cell-free DNA
isolation, library preparation, sequencing and a user-friendly data analy-
sis. This panel comprises >150 hotspots variants across 11 crucial
genes for NSCLC, such as EGFR, KRAS, TP53 and MET. The workflow
was initially tested on samples from matched tumor FFPE and plasma
collected from NSCLC patients. According to the manufacturer, results
indicated high sensitivity and significant overlapping of variants
detected in the FFPE and plasma samples with a limit of detection of
0.1% of somatic mutations.80 Another platform has been developed for
liquid biopsies, specially focused on EGFR mutation testing in plasma
samples from NSCLC patients, although different biopsies specimens
have also been used such as core-needle and cytology.81 These
approaches have emerged as useful for the monitoring of treatment
and disease progression in body fluids from NSCLC patients. In this
context, liquid cytology might also be potentially used as a specimen
FIGURE 1 The Papanicolaou stain allows the cytologic analyses of squamous cell carcinoma features (403) from two patients [Color figure
can be viewed at wileyonlinelibrary.com]
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for liquid biopsy, which is a less invasive method, easily obtained and
likely to be better tolerated than rebiopsy for patients. Another possi-
ble use of cytology is the identification of causative agents and man-
agement of patients with infectious diseases.8,74 Because the lung is
the largest epithelial surface in the body, it constitutes the major portal
for the entry of microorganisms such as viruses, bacteria and fungal
organisms.82 The diagnosis of microorganisms is based particularly on
molecular methods of nucleic acid analysis and microarrays, and classi-
fied as amplified, unamplified.83 In clinical practice, PCR is the most
common method for the detection of microorganisms such as Strepto-
coccus pneumonia, Mycoplasma pneumonia and Staphylococcus aureus,
among others. Currently, real-time PCR has been widely used because
it offers a lower risk of contamination, rapid turn-around and its sensi-
tivity allows the detection of infectious agents found in low concentra-
tions in cytological samples. More recently, studies have shown the
utility of BAL for investigation of respiratory microbiota and metabolic
profiles from HIV-infected individuals84 and patients with cystic fibro-
sis,85 these conditions being contributor conditions for lung cancer
development. So far, cytological samples have not been employed for
microbiota investigation in the pulmonary oncology field; however,
there are predictable data for attracting the attention to a high-risk
population for developing lung neoplasms. Thus, these findings rein-
force the importance of cytological samples for the lung cancer field.
2 | CONCLUDING REMARKS
The current era of personalized medicine using mutational screening
for clinical management of lung cancer patients has brought major
advances in lung cancer therapy and it has allowed the identification of
patients who could benefit from targeted therapies. Cytology samples
have become an attractive tool to be employed in association with the
histology approach.
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